Company Profile

SHILPA MEDICARE LTD.

NSE : SHILPAMEDBSE : 530549ISIN CODE : INE790G01031Industry : Pharmaceuticals & DrugsHouse : Private
BSE303.50-1.55 (-0.51 % )
PREV CLOSE (Rs.) 305.05
OPEN PRICE (Rs.) 308.50
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 657
TODAY'S LOW / HIGH (Rs.)298.55 308.50
52 WK LOW / HIGH (Rs.)190.8 433.1
NSE304.70 0.5 (+0.16 % )
PREV CLOSE(Rs.) 304.20
OPEN PRICE (Rs.) 306.50
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 304.70 (204 )
VOLUME 9309
TODAY'S LOW / HIGH(Rs.) 301.00 308.60
52 WK LOW / HIGH (Rs.)208.1 435.05

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 1.98936
Dividend Yield(%)
TTM EPS (Rs.)
P/E Ratio
Book Value (Rs.)
Face Value (Rs.)
MCap (Rs. in Mn)
Price/Earning (TTM)
Price/Sales (TTM)
Price/Book (MRQ)
PAT Margin (%) 18.69
ROCE (%) 11.28
Incorporation Year : 1987

Management Info :

Omprakash Inani - Chairman Vishnukanth Chaturbhuj Bhutada - Managing Director

Registered Office :

Address : Shilpa House,#12-6-214/a1,Hyderabad Road,
Raichur,
Karnataka-584135

Phone : 08532-238704

Website : www.vbshilpa.com

Registrar's Details : KFIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
04Dec12-04-2019$Shilpa Medicare receives EIR from USFDA for Raichur API manufacturing site Shilpa Medicare receives EIR

Shilpa Medicare has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at API manufacturing site located at Raichur in the state of Karnataka. The authority had conducted inspection during the period July 22, 2019 to July 26, 2019.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare has received Establishment Inspection Report (E..
03Dec12-03-2019$Shilpa Medicare submits related party transactions Shilpa Medicare submits rela

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Shilpa Medicare has informed about submission of Related Party Transactions on consolidated basis in the format as per the relevant Accounting Standards for the Half Year ended 30th September, 2019. 

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 23(9) of the Securities and Exchange Boa..
06Nov11-06-2019$Shilpa Medicare gets USFDA’s nod for Erlotinib Tablets Shilpa Medicare gets USFDAâ€

Shilpa Medicare has received the US Food and Drug Administration (USFDA) final approval for its ANDA, Erlotinib Tablets, 25 mg, 100 mg, and 150 mg on November 05, 2019.

Erlotinib Tablets, 25 mg, 100 mg, and 150 mg is a generic equivalent of reference listed drug (RLD) TARCEVA used in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) and locally advanced, unresectable or metastatic pancreatic cancer as recommended in the label approved by USFDA.

According to IQVIA MAT Q2 2019 data, the US market for Erlotinib Tablets is approximately $172 million.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare has received the US Food and Drug Administratio..
06Nov11-06-2019$Shilpa Medicare surges on getting USFDA’s nod for Erlotinib Tablets Shilpa Medicare surges on ge

Shilpa Medicare is currently trading at Rs. 319.05, up by 9.20 points or 2.97% from its previous closing of Rs. 309.85 on the BSE.

The scrip opened at Rs. 301.00 and has touched a high and low of Rs. 325.30 and Rs. 301.00 respectively. 

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 433.10 on 23-Apr-2019 and a 52 week low of Rs. 190.80 on 04-Sep-2019.

Last one week high and low of the scrip stood at Rs. 332.10 and Rs. 275.00 respectively. The current market cap of the company is Rs. 2551.79 crore.

The promoters holding in the company stood at 53.80%, while Institutions and Non-Institutions held 26.95% and 19.25% respectively.

Shilpa Medicare has received the US Food and Drug Administration (USFDA) final approval for its ANDA, Erlotinib Tablets, 25 mg, 100 mg, and 150 mg on November 05, 2019. Erlotinib Tablets, 25 mg, 100 mg, and 150 mg is a generic equivalent of reference listed drug (RLD) TARCEVA used in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) and locally advanced, unresectable or metastatic pancreatic cancer as recommended in the label approved by USFDA.

According to IQVIA MAT Q2 2019 data, the US market for Erlotinib Tablets is approximately $172 million.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare is currently trading at Rs. 319.05, up by 9.20..
25Oct10-25-2019$Shilpa Medicare gets EIR from USFDA for Finished Dosage Formulation Facility Shilpa Medicare gets EIR fro

Shilpa Medicare has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) on October 2019, for the Finished Dosage Formulation Facility (Sterile and Non-sterile Dosage Forms) located at 5-20 to 5-26, Pharmaceutical Formulations SEZ, APIIC, Jadcherla in the state of Telangana.

The company's finished dosage form facility was inspected by US FDA from August 29, 2019 to September 6, 2019. USFDA has concluded the Inspection, with determination that the inspection classification of this facility is ‘voluntary action indicated’ (VAI). This facility is in acceptable state of compliance with regards to current good manufacturing practice (CGMP).

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare has received Establishment Inspection Report (E..
Financials More
Rs. in Millions
QTR Sep 19 ANNUAL 19
Net Profit530.971241.06
Gross Profit 633.2 1556
Operating Profit 734.021894.37
Net Sales 2365.326638.79
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Astrazeneca Pharma I (BSE)
 2761.55 (4.11%)
M.Cap ( in Cr)
6903.88
Sanofi India (BSE)
 7018.65 (0.70%)
M.Cap ( in Cr)
16164.39
Divis Lab (BSE)
 1806.35 (1.30%)
M.Cap ( in Cr)
47952.92
Hester Biosciences (BSE)
 1574.70 (1.33%)
M.Cap ( in Cr)
1339.58
Torrent Pharma (BSE)
 1867.95 (0.94%)
M.Cap ( in Cr)
31607.34
Shareholding Pattern More
PROMOTERS 53.8 %
NON-INSTITUTION 19.25 %
FI/BANKS/INSURANCE 0.49 %
MUTUAL FUNDS/UTI 0.04 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes